PCDH19 and epilepsy: Refractory epilepsy, caused by PCDH19 pathogenic variants, is a highly drug-resistant condition, but molecular diagnosis has allowed us to apply Ganaxolone in our patients, a drug whose effectiveness in females with PCDH19 variants has been recently confirmed in clinical trials [19].